PIQUR Therapeutics AG-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:PIQUR Therapeutics AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014248
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
PIQUR Therapeutics AG (PIQUR) is a clinical-stage pharmaceutical company that discovers and develops anti-cancer drugs. The company develops innovative small molecule therapeutics based on lipid kinase (PI3K) and mTOR inhibitior for the treatment of cancer and inflammatory diseases. Its pipeline products include PQR-309, PQR-620, PQR-530, PQR-514, PQR-6XX, and PI3K/mTOR inhibitors. PIQUR’s lead compound PQR309, is a potent small molecule with balanced pan-PI3K/mTOR selectivity. The company’s target therapy areas include oncology, central nervous system, ophthalmology, and dermatology, among others. It conducts research in the areas of oncology. PIQUR serves patients and the medical community. The company partners with pharmaceutical and biotech companies. PIQUR is headquartered in Basel, Switzerland.

PIQUR Therapeutics AG – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
PIQUR Therapeutics AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
PIQUR Therapeutics Raises USD19 Million in Series A2 Financing 10
PIQUR Therapeutics Raises Additional US$16 Million In Series A Financing 11
PIQUR Therapeutics Raises US$20 Million In Series A Financing 12
PIQUR Therapeutics Raises Funds in Extended Seed Financing 13
PIQUR Therapeutics Raises USD5.5 Million in Seed Financing 14
Partnerships 15
Laboratoires Pierre Fabre Enters into Licensing Agreement with PIQUR Therapeutics 15
Eisai Enters into Agreement with PIQUR Therapeutics 16
Licensing Agreements 17
PIQUR Therapeutics Expands Licensing Agreement with University of Basel for PQR309 17
PIQUR Therapeutics AG – Key Competitors 18
PIQUR Therapeutics AG – Key Employees 19
PIQUR Therapeutics AG – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Product Approvals 21
Apr 27, 2017: PIQUR Receives EMA Orphan Drug Designation for PQR309 in Diffuse Large B-Cell Lymphoma 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Key Facts 2
PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
PIQUR Therapeutics AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
PIQUR Therapeutics AG, Deals By Therapy Area, 2011 to YTD 2017 8
PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
PIQUR Therapeutics Raises USD19 Million in Series A2 Financing 10
PIQUR Therapeutics Raises Additional US$16 Million In Series A Financing 11
PIQUR Therapeutics Raises US$20 Million In Series A Financing 12
PIQUR Therapeutics Raises Funds in Extended Seed Financing 13
PIQUR Therapeutics Raises USD5.5 Million in Seed Financing 14
Laboratoires Pierre Fabre Enters into Licensing Agreement with PIQUR Therapeutics 15
Eisai Enters into Agreement with PIQUR Therapeutics 16
PIQUR Therapeutics Expands Licensing Agreement with University of Basel for PQR309 17
PIQUR Therapeutics AG, Key Competitors 18
PIQUR Therapeutics AG, Key Employees 19

★海外企業調査レポート[PIQUR Therapeutics AG-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Samsung Securities Co., Ltd. (016360):企業の財務・戦略的SWOT分析
    Samsung Securities Co., Ltd. (016360) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • WESCO International Inc (WCC):企業の財務・戦略的SWOT分析
    WESCO International Inc (WCC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Genetic Signatures Ltd (GSS):企業の製品パイプライン分析
    Summary Genetic Signatures Ltd (Genetic Signatures) formerly Human Genetic Signatures Pty Ltd, is a molecular diagnostics company. The company designs and manufactures real-time polymerase chain reaction (PCR) based products for the detection of infectious diseases under the EasyScreen brand. It off …
  • Virco Mfg Corp (VIRC):企業の財務・戦略的SWOT分析
    Summary Virco Mfg Corp (Virco) operates as a manufacturer and supplier of furniture and equipment for educational and commercial applications. The company offers chairs, desks, tables, filing cabinets, mobile cabinets, media towers, chair trucks, table trucks, bookcases, and accessories. It provides …
  • Daiwa House Industry Co., Ltd.:企業の戦略・SWOT・財務分析
    Daiwa House Industry Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Daiwa House Industry Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Grupo Industrial Saltillo, S.A.B. de C.V.:企業の戦略・SWOT・財務情報
    Grupo Industrial Saltillo, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report Summary Grupo Industrial Saltillo, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • MegaChips Corp (6875):企業の財務・戦略的SWOT分析
    MegaChips Corp (6875) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • F J Benjamin Holdings Ltd.:企業の戦略・SWOT・財務分析
    F J Benjamin Holdings Ltd. - Strategy, SWOT and Corporate Finance Report Summary F J Benjamin Holdings Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Horizon Discovery Group Plc (HZD):企業の財務・戦略的SWOT分析
    Summary Horizon Discovery Group Plc (Horizon Discovery) is a life science company that discovers and develops genetically-modified cell lines using a proprietary translational genomics platform. The company offers products such as cell lines, reference standards and in vivo models. It also offers se …
  • Spherix Inc (SPEX):企業の財務・戦略的SWOT分析
    Spherix Inc (SPEX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Avista Corporation (AVA):電力:M&Aディール及び事業提携情報
    Summary Avista Corporation (Avista) is an electric and natural gas utility. The company produces, transmits, and distributes electricity; and supplies natural gas on retail and wholesale basis. It sources electricity from its facilities and contracted hydroelectric, thermal and wind generation facil …
  • VentriPoint Diagnostics Ltd-医療機器分野:企業M&A・提携分析
    Summary VentriPoint Diagnostics Ltd (Ventripoint) is a medical device company that manufactures and distributes diagnostic tools and monitoring devices for patients with heart diseases. The company offers ventripoint diagnostic system, which is a cardiovascular monitoring and measurement device. Its …
  • Newpark Resources Inc (NR):企業の財務・戦略的SWOT分析
    Newpark Resources Inc (NR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Sentara Healthcare Inc:企業の戦略的SWOT分析
    Sentara Healthcare Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Therapeutic Solutions International Inc (TSOI)-医療機器分野:企業M&A・提携分析
    Summary Therapeutic Solutions International Inc (Therapeutic Solutions) is a pharmaceutical company that provides supplement products. The company offers ProJuvenol, T-Rx and Vital. Its ProJuvenol consists of anti-aging ingredients which helps for a healthy functionality for everyday living and prom …
  • Park Hotels & Resorts Inc (PK):企業の財務・戦略的SWOT分析
    Park Hotels & Resorts Inc (PK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Myelin Repair Foundation-製薬・医療分野:企業M&A・提携分析
    Summary Myelin Repair Foundation (MRF) is a medical research organization that discovers and develops myelin repair therapeutics for multiple sclerosis. The organization publishes various peer-reviewed scientific articles, identifies different myelin repair treatment targets and discovers multiple r …
  • BioCryst Pharmaceuticals Inc (BCRX):企業の財務・戦略的SWOT分析
    BioCryst Pharmaceuticals Inc (BCRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Luminex Corp (LMNX)-医療機器分野:企業M&A・提携分析
    Summary Luminex Corp (Luminex) is a medical devices company which develops, manufactures and markets proprietary biological testing technologies. The company offers wide range of products including instruments, assays, reagents and accessories, software and replacement parts. Its proprietary technol …
  • Attica Bank S.A.
    Attica Bank S.A. - Strategy, SWOT and Corporate Finance Report Summary Attica Bank S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆